Breast cancers arising in subjects with germline BRCA1 or BRCA2 mutations: Different biological and clinical entities with potentially diverse therapeutic opportunities.

doi:10.1016/j.critrevonc.2023.104109

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Breast cancers arising in subjects with germline BRCA1 or BRCA2 mutations: Different biological and clinical entities with potentially diverse therapeutic opportunities.

Critical reviews in oncology/hematology - 1 Oct 2023

Zattarin Emma, Taglialatela Ida, Lobefaro Riccardo, Leporati Rita, Fucà Giovanni, Ligorio Francesca, Sposetti Caterina, Provenzano Leonardo, Azzollini Jacopo, Vingiani Andrea, Ferraris Cristina, Martelli Gabriele, Manoukian Siranoush, Pruneri Giancarlo, de Braud Filippo, Vernieri Claudio

Abstract excerpt

Breast cancers (BCs) arising in carriers of germline BRCA1 and BRCA2 pathogenic variants (PVs) have long been considered as indistinguishable biological and clinical entities. However, the loss of function of BRCA1 or BRCA2 proteins has different consequences in terms of tumor cell reliance on estrogen receptor signaling and tumor microenvironment composition. Here, we review accumulating preclinical and clinical...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to BRCA gene mutations in cancer

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to BRCA1 Protein

Share to BRCA2 Protein

Share to Germ Cells

Share to Immune Checkpoint Inhibitors

Share to Mutation

Share to Triple Negative Breast Neoplasms

Share to Tumor Microenvironment

Source

Open in PubMed

Identifiers

PMID: 37643668
DOI: 10.1016/j.critrevonc.2023.104109

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Breast cancers arising in subjects with germline BRCA1 or BRCA2 mutations: Different biological and clinical entities with potentially diverse therapeutic opportunities.PMID 37643668Read ↗

Breast Cancer: A Molecularly Heterogenous Disease Needing Subtype-Specific TreatmentsSemantic proximity Read ↗

Breast Cancer: Epidemiology, Molecular Classification, Diagnostics and Evolving Treatment Paradigms.Semantic proximity Read ↗

Pathology of BRCA1- and BRCA2-associated Breast Cancers: Known and Less Known Connections.Semantic proximity Read ↗

Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease.Semantic proximity Read ↗

Management of Hereditary Breast Cancer: American Society of Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology Guideline.Semantic proximity Read ↗

Emerging Protein Targets in Triple Negative Breast Cancer: Beyond Conventional TherapySemantic proximity Read ↗

The Present and Future of Clinical Management in Metastatic Breast CancerSemantic proximity Read ↗

Prognostic significance of germline BRCA mutations in patients with HER2-POSITIVE breast cancer.Semantic proximity Read ↗

BRCA in breast cancer: ESMO clinical recommendations.Semantic proximity Read ↗

Hereditary breast cancer: part II. Management of hereditary breast cancer: implications of molecular genetics and pathology.Semantic proximity Read ↗

Beyond PARP Inhibitors in Advanced Breast Cancer Patients with Germline BRCA1/2 Mutations: Focus on CDK4/6-Inhibitors and Data Review on Other Biological TherapiesSemantic proximity Read ↗

Molecular and Cellular Heterogeneity in Breast CancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.